Alexion's Soliris Blood Drug Draws New Patent Cases

Law360, New York (March 19, 2007, 12:00 AM EDT) -- Just days after Alexion Pharmaceuticals Inc.’s blood antibody drug Soliris was approved by the United States Food and Drug Administration, two parties have filed a lawsuit claiming the drug infringes on their patents.

Alexion’s Soliris drug is the first humanized antibody approved by the FDA to treat a rare blood disorder, paroxysmal nocturnal humoglobinuria (PNH), which strikes one in a million people and can lead to disability and a premature death.

The drug does not cure PNH, but rather stops the body from breaking down abnormally...
To view the full article, register now.